Loading...

XAIR BEYOND AIR INC Product Launches 8-K Filing

BYND

XR

BEYOND AIR INC

(XAIR)

2024 8-K

Show Summary

Summary

Reverse Stock Split

Share Sale Agreement

Management Change

Equity Offering

Financial Results

Nasdaq Compliance Notice

Accounting Firm Change

Clinical Trial Approval

CE Mark Approval

Annual Meeting Results

Financial Results

Annual Meeting Notice

Securities Offering

Financial Results and Delis...

Loan Agreement Amendment an...

Equity Incentive Plan Approval

Termination of Sales Agreement

Financial Results and Consu...

Earnings Reports

Earnings Report

Financial Results Announcement

Equity Incentive Plan Approved

Earnings Report

External Links:

Beyond Cancer, Ltd., a majority-owned affiliate of Beyond Air, Inc., received approval from the Israeli Ministry of Health for a Phase 1b clinical trial using Low Volume UNO in combination with anti-PD-1 therapy.

AI Assistant

BEYOND AIR INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.